Constipation News and Research

Latest Constipation News and Research

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII.

25 Mar 2015

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions.

19 Mar 2015

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014.

16 Mar 2015

TWi Biotechnology obtains Rare Disease Drug designation in Taiwan for use of AC-203 to treat EBS

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received the designation of Rare Disease Drug by Taiwan FDA for use of AC-203 to treat Epidermolysis Bullosa Simplex (EBS), and is eligible for applying for coverage under National Health Insurance Administration.

10 Mar 2015

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).

8 Mar 2015

Non-drug approaches work better in people with Alzheimer's disease, dementia

Doctors write millions of prescriptions a year for drugs to calm the behavior of people with Alzheimer's disease and other types of dementia. But non-drug approaches actually work better, and carry far fewer risks, experts conclude in a new report.

4 Mar 2015

Key questions about colorectal cancer answered

Colorectal cancer is the fourth most common cancer in the U.S., with more than 136,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years.

4 Mar 2015

Anticholinergic medications associated with pneumonia risk in older people

Taking commonly used medications with anticholinergic effects is associated with a significantly higher risk for developing pneumonia in a study of more than 3,000 older Group Health patients living in the community--not in nursing homes.

3 Mar 2015

Health Canada: Parents advised not to feed honey to infants less than one year old

In Canada, honey is the only food which has been linked to infant botulism – a rare but serious illness that is caused by ingesting the bacterium C. botulinum.

12 Feb 2015

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

10 Feb 2015

Added benefit of lurasidone drug not proven for schizophrenia

The drug lurasidone (trade name Latuda) has been available since November 2014 for the treatment of adults with schizophrenia. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

8 Feb 2015

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

Theravance Biopharma, Inc. and Mylan Inc. today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.

2 Feb 2015

Temple University Hospital participating in trial to test vibrating capsule for chronic constipation treatment

Chronic constipation is a common problem that affects approximately 15 percent of the U.S. population, according to the American Gastroenterological Association. It can be painful and lead to a reduction in a patient's quality of life. Temple University Hospital is the only hospital in the Philadelphia region participating in a nationwide clinical trial to test an innovative, vibrating capsule for patients with chronic constipation.

31 Jan 2015

Shire announces FDA approval of Vyvanse Capsules for binge eating disorder

Shire plc announced today that the U.S. Food and Drug Administration approved Vyvanse (lisdexamfetamine dimesylate) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults, shown to significantly reduce the mean number of binge days per week.

30 Jan 2015

Nonmotor symptoms cluster in Parkinson’s disease patients

Nonmotor symptoms tend to appear in specific clusters in patients with Parkinson’s disease and often predate the onset of motor symptoms, research shows.

16 Jan 2015

Disturbed gut microbiome linked to Parkinson’s disease

Research suggests that the intestinal microbiome may be altered in patients with Parkinson’s disease, with some alterations being specific to the motor subtype.

16 Jan 2015

New research sheds light on the role of Sox10 protein in Hirschsprung's disease patients

Defects in the protein Sox10, a transcription factor that regulates gene expression, may play a role in the development of post-operative GI dysfunction in Hirschsprung's disease patients, according to new research published in Cellular and Molecular Gastroenterology and Hepatology, the new basic science journal of the American Gastroenterological Association.

16 Jan 2015

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.

8 Jan 2015

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

31 Dec 2014

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic.

30 Dec 2014

Constipation News and Research

Latest Constipation News and Research

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Egalet announces net revenues of $1.9 million for 2014

TWi Biotechnology obtains Rare Disease Drug designation in Taiwan for use of AC-203 to treat EBS

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Non-drug approaches work better in people with Alzheimer's disease, dementia

Key questions about colorectal cancer answered

Anticholinergic medications associated with pneumonia risk in older people

Health Canada: Parents advised not to feed honey to infants less than one year old

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Added benefit of lurasidone drug not proven for schizophrenia

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

Temple University Hospital participating in trial to test vibrating capsule for chronic constipation treatment

Shire announces FDA approval of Vyvanse Capsules for binge eating disorder

Nonmotor symptoms cluster in Parkinson’s disease patients

Disturbed gut microbiome linked to Parkinson’s disease

New research sheds light on the role of Sox10 protein in Hirschsprung's disease patients

FDA approves RYTARY for Parkinson's disease treatment

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Constipation News and Research

Latest Constipation News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in